Treatment outcomes of the LBBAP
Six studies assessed the effects of LBBAP on NT-pro BNP levels between
pre- and post-procedural treatment. LBBAP significantly lowered NT-pro
BNP levels, with mean difference of −674.89 pg/ml (95% CI −1103.72 to
−246.06, I2 = 93.8%). Furthermore, 13 studies assessed the
effects of LBBAP on NYHA classification between pre- and post-procedural
treatment, over 6–12 months of follow-up. LBBAP was also associated
with a significant improvement of NYHA classification, with a mean
difference of −1.25 (95% CI −1.46 to −1.04, I2 = 87.9%), with
no differences between the Chinese and non-Chinese population (−1.27 vs.
−1.24, p= 0.90) and the PICM and non-PICM patients (−1.02 vs. −1.31, p =
0.28).